An osteoporosis treatment from Thousand Oaks biotech giant Amgen received FDA approval to treat postmenopausal women, who are at a high risk for bone fractures. The approval follows data from two Phase 3 studies of the drug, called Evenity, that showed significant reductions in spine fractures and increases in bone mineral density compared to a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
